NO20061788L - HIV-replikasjonshemmede purinderivater - Google Patents

HIV-replikasjonshemmede purinderivater

Info

Publication number
NO20061788L
NO20061788L NO20061788A NO20061788A NO20061788L NO 20061788 L NO20061788 L NO 20061788L NO 20061788 A NO20061788 A NO 20061788A NO 20061788 A NO20061788 A NO 20061788A NO 20061788 L NO20061788 L NO 20061788L
Authority
NO
Norway
Prior art keywords
formula
radical
hiv replication
purine derivatives
compound
Prior art date
Application number
NO20061788A
Other languages
English (en)
Inventor
Jan Heeres
Marc Rene De Jonge
Lucien Maria Henricus Koymans
Hendrik Maarten Vinkers
Frederik Frans Desire Daeyaert
Paulus Joannes Lewi
Paul Adriaan Jan Janssen
Ruben Gerardus George Leenders
Dirk Alfons Leo Vandenput
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20061788L publication Critical patent/NO20061788L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelsen av en forbindelse med formel (I) for fremstillingen av et medikament for forebyggingen eller behandlingen av HIV-infeksjon hvori forbindelsen med formel (I) er en forbindelse med formel et N-oksid, et farmasøytisk akseptabelt addisjonssalt, et kvaternært amin eller en stereo-kjemisk isomer form derav, hvori A og B hver representerer et radikal med formel og hvori -C-D- representerer et bivalent radikal med formel -N=CH-NR17- (c-1); eller -NR17-CH=N- (c-2); forutsatt at når A representerer et radikal med formel (a) så representerer B et radikal med formel (b) og når A representerer et radikal med formel (b) så representerer B et radikal med formel (a).
NO20061788A 2003-09-25 2006-04-24 HIV-replikasjonshemmede purinderivater NO20061788L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350659 2003-09-25
PCT/EP2004/052262 WO2005028479A2 (en) 2003-09-25 2004-09-21 Hiv replication inhibiting purine derivatives

Publications (1)

Publication Number Publication Date
NO20061788L true NO20061788L (no) 2006-04-24

Family

ID=34354400

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061788A NO20061788L (no) 2003-09-25 2006-04-24 HIV-replikasjonshemmede purinderivater

Country Status (19)

Country Link
US (1) US8026245B2 (no)
EP (1) EP1668011B1 (no)
JP (1) JP5506751B2 (no)
KR (1) KR20060121878A (no)
CN (1) CN100475815C (no)
AP (1) AP2006003517A0 (no)
AT (1) ATE500254T1 (no)
AU (1) AU2004274185B2 (no)
BR (1) BRPI0414791A (no)
CA (1) CA2535313C (no)
DE (1) DE602004031641D1 (no)
EA (1) EA009734B1 (no)
ES (1) ES2361835T3 (no)
IL (1) IL174467A0 (no)
MX (1) MXPA06002069A (no)
NO (1) NO20061788L (no)
TW (1) TW200518758A (no)
WO (1) WO2005028479A2 (no)
ZA (1) ZA200602440B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
AU2005218655A1 (en) * 2004-03-02 2005-09-15 Neurogen Corporation Aryl substituted purine analogues
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ME01512B (me) 2004-08-25 2014-04-20 Ardea Biosciences Inc S-triazolil alfa-merkaptoacetanilida kao inhibitori HIV reversne transkriptaze
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
ATE541848T1 (de) 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
BRPI0610824A8 (pt) * 2005-05-16 2017-04-04 Prometic Pharma Smt Ltd Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2132211A4 (en) * 2006-11-09 2011-12-07 Ardea Biosciences Inc 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER
EP2121613A2 (en) 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
NZ590784A (en) 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
MX2011000837A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa triciclica.
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
ES2567168T3 (es) 2009-11-12 2016-04-20 F. Hoffmann-La Roche Ag Compuestos purina y pirazolopirimidina N7-sustituidos, composiciones y métodos de utilización
EP2528917B1 (en) 2010-01-27 2016-10-19 Vertex Pharmaceuticals Incorporated Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
EP2582702A1 (en) 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
AU2011209649A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
WO2015115673A1 (en) 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
MX393816B (es) 2014-12-18 2025-03-24 Nissan Chemical Ind Ltd Compuesto de cetona u oxima, y herbicida.
CN110300590A (zh) * 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
US20210380540A1 (en) * 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CN114805369B (zh) * 2022-05-30 2023-05-16 自贡市第四人民医院(自贡市急救中心) 一种2，6-二取代嘌呤类化合物及制备方法及应用
KR20250101955A (ko) * 2023-12-27 2025-07-04 주식회사 에이조스바이오 신규 퓨린계 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
NZ506679A (en) 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
ID28376A (id) 1998-11-10 2001-05-17 Janssen Pharmaceutica Nv Pirimidina yang menghambat replikasi hiv
US6414147B1 (en) * 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6897307B2 (en) * 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
ATE541848T1 (de) * 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv

Also Published As

Publication number Publication date
CA2535313C (en) 2012-07-17
EP1668011B1 (en) 2011-03-02
JP2007506707A (ja) 2007-03-22
EP1668011A2 (en) 2006-06-14
AU2004274185B2 (en) 2009-12-10
AU2004274185A1 (en) 2005-03-31
WO2005028479A2 (en) 2005-03-31
JP4825672B2 (ja) 2011-11-30
WO2005028479A3 (en) 2005-06-16
US20060293330A1 (en) 2006-12-28
IL174467A0 (en) 2006-08-01
CN1856496A (zh) 2006-11-01
EA009734B1 (ru) 2008-02-28
BRPI0414791A (pt) 2006-11-21
MXPA06002069A (es) 2006-05-19
JP2012006945A (ja) 2012-01-12
TW200518758A (en) 2005-06-16
KR20060121878A (ko) 2006-11-29
ZA200602440B (en) 2007-09-26
US8026245B2 (en) 2011-09-27
EA200600648A1 (ru) 2006-08-25
AP2006003517A0 (en) 2006-02-28
ATE500254T1 (de) 2011-03-15
DE602004031641D1 (de) 2011-04-14
JP5506751B2 (ja) 2014-05-28
CA2535313A1 (en) 2005-03-31
ES2361835T3 (es) 2011-06-22
CN100475815C (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
EA200600648A1 (ru) Производные пурина, ингибирующие репликацию вич
GEAP202416435A (en) Anti-viral compounds
GB0612423D0 (en) Therapeutic agents
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
NO20054143L (no) Pyrimidinderivater for forhindringen av HIV-infeksjon
DE602004024375D1 (de) Carboxamidderivate
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
NO20081844L (no) Terapeutiske forbindelser
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
GB0413087D0 (en) Therapeutic compounds
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
SE0202429D0 (sv) Novel Compounds
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application